Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NBP), licensed exclusive worldwide rights, excluding Greater China, to Hiteck's investigational NGF eye drop HT006.2.2, which Visara will develop as VIS-102 for neurotrophic keratitis. Hiteck retains Greater China rights, where a Phase 1b study in severe neurotrophic keratitis showed 50% complete corneal healing in the highest-dose cohort after an 8-week course versus 14% on vehicle control, with only mild treatment-related ocular adverse events.
Key figures
- Drug Name
- HT006.2.2 / VIS-102
- Phase Of Trial
- Phase 1b
- Crossover 4week healing
- 43%
- Complete healing vehicle
- 14%
- Complete healing top dose
- 50%
- Ex granterchina territory
- worldwide excluding Greater China
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.